Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib-Reference-Cited by-同舟云学术

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Published:2016-08-25 Issue:45 Volume:7 Page:72622-72633
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Rimassa Lorenza¹,Abbadessa Giovanni²,Personeni Nicola¹³,Porta Camillo⁴,Borbath Ivan⁵,Daniele Bruno⁶,Salvagni Stefania⁷,Van Laethem Jean-Luc⁸,Van Vlierberghe Hans⁹,Trojan Jörg¹⁰,De Toni Enrico N.¹¹,Weiss Alan¹²,Miles Steven¹³,Gasbarrini Antonio¹⁴,Lencioni Monica¹⁵,Lamar Maria E.²,Wang Yunxia²,Shuster Dale¹⁶,Schwartz Brian E.²,Santoro Armando¹¹⁷

Affiliation:

1. Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy

2. ArQule, Burlington, MA, USA

3. Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Milan, Italy

4. Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

5. Cliniques Universitaires Saint-Luc, Brussels, Belgium

6. G Rummo Hospital, Benevento, Italy

7. Azienda Ospedaliera Universitaria Sant'Orsola-Malpighi, Bologna, Italy

8. Erasme University Hospital, Brussels, Belgium

9. Ghent University Hospital, Ghent, Belgium

10. J W Goethe-University Hospital, Frankfurt, Germany

11. Klinikum der Universitaet Muenchen-Grosshadern, Munich, Germany